380 related articles for article (PubMed ID: 26404261)
1. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
2. SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.
Daley BR; Vieira HM; Rao C; Hughes JM; Beckley ZM; Huisman DH; Chatterjee D; Sealover NE; Cox K; Askew JW; Svoboda RA; Fisher KW; Lewis RE; Kortum RL
Proc Natl Acad Sci U S A; 2023 Nov; 120(47):e2313137120. PubMed ID: 37972068
[TBL] [Abstract][Full Text] [Related]
3. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer.
Molina-Arcas M; Moore C; Rana S; van Maldegem F; Mugarza E; Romero-Clavijo P; Herbert E; Horswell S; Li LS; Janes MR; Hancock DC; Downward J
Sci Transl Med; 2019 Sep; 11(510):. PubMed ID: 31534020
[TBL] [Abstract][Full Text] [Related]
4. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
[TBL] [Abstract][Full Text] [Related]
5. PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract][Full Text] [Related]
6. BRAF-Directed Therapy in Metastatic Colorectal Cancer.
Korphaisarn K; Kopetz S
Cancer J; 2016; 22(3):175-8. PubMed ID: 27341594
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.
Catalanotti F; Solit DB; Pulitzer MP; Berger MF; Scott SN; Iyriboz T; Lacouture ME; Panageas KS; Wolchok JD; Carvajal RD; Schwartz GK; Rosen N; Chapman PB
Clin Cancer Res; 2013 Apr; 19(8):2257-64. PubMed ID: 23444215
[TBL] [Abstract][Full Text] [Related]
8. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
[TBL] [Abstract][Full Text] [Related]
9. Comparison of growth factor signalling pathway utilisation in cultured normal melanocytes and melanoma cell lines.
Kim JE; Stones C; Joseph WR; Leung E; Finlay GJ; Shelling AN; Phillips WA; Shepherd PR; Baguley BC
BMC Cancer; 2012 Apr; 12():141. PubMed ID: 22475322
[TBL] [Abstract][Full Text] [Related]
10. MUC1-C is necessary for SHP2 activation and BRAF inhibitor resistance in BRAF(V600E) mutant colorectal cancer.
Morimoto Y; Yamashita N; Hirose H; Fushimi A; Haratake N; Daimon T; Bhattacharya A; Ahmad R; Suzuki Y; Takahashi H; Kufe DW
Cancer Lett; 2023 Apr; 559():216116. PubMed ID: 36878307
[TBL] [Abstract][Full Text] [Related]
11. Targeting mTOR network in colorectal cancer therapy.
Wang XW; Zhang YJ
World J Gastroenterol; 2014 Apr; 20(15):4178-88. PubMed ID: 24764656
[TBL] [Abstract][Full Text] [Related]
12. Polo-like Kinase 1 Inhibition in KRAS-Mutated Metastatic Colorectal Cancer.
Stebbing J; Bullock AJ
Clin Cancer Res; 2024 May; 30(10):2005-2007. PubMed ID: 38470499
[TBL] [Abstract][Full Text] [Related]
13. Glycolysis-non-canonical glutamine dual-metabolism regulation nanodrug enhanced the phototherapy effect for pancreatic ductal adenocarcinoma treatment.
Qiao J; Liu S; Huang Y; Zhu X; Xue C; Wang Y; Xiong H; Yao J
J Colloid Interface Sci; 2024 Jul; 665():477-490. PubMed ID: 38429120
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of BRAF and mTOR in
Sen S; Tanaka R; Khatua S; Zaky W; Janku F; Penas-Prado M; Weathers SP; Behrang A; Roszik J; Subbiah V
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32843426
[TBL] [Abstract][Full Text] [Related]
15. Germline variation in RASAL2 may predict survival in patients with RAS-activated colorectal cancer.
Wills C; Watts K; Maughan TS; Fisher D; Al-Tassan NA; Houlston RS; Escott-Price V; Cheadle JP
Genes Chromosomes Cancer; 2023 Jun; 62(6):332-341. PubMed ID: 36790221
[TBL] [Abstract][Full Text] [Related]
16. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
Yakkala PA; Naaz F; Shafi S; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
[TBL] [Abstract][Full Text] [Related]
17. Tumor and Systemic Immunomodulatory Effects of MEK Inhibition.
Dennison L; Mohan AA; Yarchoan M
Curr Oncol Rep; 2021 Feb; 23(2):23. PubMed ID: 33547983
[TBL] [Abstract][Full Text] [Related]
18. Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models.
Puliga E; De Bellis C; Vietti Michelina S; Capeloa T; Migliore C; Orrù C; Baiocchi GL; De Manzoni G; Pietrantonio F; Reddavid R; Fumagalli Romario U; Ambrogio C; Corso S; Giordano S
Gastric Cancer; 2024 May; 27(3):473-483. PubMed ID: 38261067
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer.
Yu C; Luo D; Yu J; Zhang M; Zheng X; Xu G; Wang J; Wang H; Xu Y; Jiang K; Xu J; Ma X; Jing J; Shi H
Oncogene; 2022 Jan; 41(2):191-203. PubMed ID: 34718347
[TBL] [Abstract][Full Text] [Related]
20. Concomitant MEK and Cyclin Gene Alterations: Implications for Response to Targeted Therapeutics.
Kato S; Adashek JJ; Shaya J; Okamura R; Jimenez RE; Lee S; Sicklick JK; Kurzrock R
Clin Cancer Res; 2021 May; 27(10):2792-2797. PubMed ID: 33472910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]